Clinical Trial Results:
A Phase 3, Multi-Center, Placebo-Controlled, Randomized,
Double-Blind, 12-Week Study With an Open-Label Extension
to Evaluate the Efficacy and Safety of AMR101 in Patients
With Fasting Triglyceride Levels =>500 mg/dL and <=2000 mg/dL:
The AMR101 MARINE Study
Summary
|
|
EudraCT number |
2009-010520-25 |
Trial protocol |
NL DE DK FI IT |
Global completion date |
19 Oct 2010
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
01 Mar 2022
|
First version publication date |
01 Mar 2022
|
Other versions |
|
Summary report(s) |
amr-01-01-0016 synopsis |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.